Can Antibiotics Treat Ulcerative Colitis? What a Cochrane Review Found

Ulcerative colitis is driven partly by shifts in gut bacteria. So the idea of using antibiotics to restore a healthier microbial balance sounds logical. But does the clinical evidence support it? A Cochrane systematic review pooled the trial data to find out.

Why Researchers Are Testing Antibiotics for UC

People with UC consistently show changes in gut bacterial composition compared to those without the condition. Some researchers have hypothesised that targeting specific bacteria could disrupt the inflammatory cycle and help restore remission. This led to a number of randomised controlled trials testing various antibiotic regimens, which the Cochrane Collaboration then synthesised into a systematic review (PMID 35583095, Cochrane Database of Systematic Reviews).

What the Review Found

The Cochrane review pooled data from multiple randomised trials comparing antibiotics against placebo or standard care in people with active UC or UC in remission.

Key findings included:

Some regimens outperformed placebo. Rifaximin (a non-absorbable antibiotic that acts mainly in the gut) and certain combination regimens including neomycin, tetracycline, and ampicillin were associated with higher remission rates than placebo in specific trials.

Evidence certainty was moderate to low. Most included trials were small and used different antibiotic protocols, doses, and outcome measures, making direct comparison difficult. The reviewers graded certainty as mostly moderate or low rather than high.

Maintenance data were limited. The majority of trials looked at inducing remission during a flare. Far fewer examined whether antibiotics help keep UC quiet over the longer term.

The Risks Are Real

Antibiotics are not a straightforward add-on for UC. Several concerns temper the cautious optimism in the data.

Microbiome disruption. The same antibiotics intended to correct bacterial imbalance can paradoxically reduce gut microbial diversity, which may complicate long-term IBD management.

Antibiotic resistance. Repeated or prolonged courses increase the risk of resistant organisms, both at the individual and population level.

Side-effects that resemble flares. Diarrhoea, nausea, and abdominal cramping are common antibiotic side-effects that are hard to distinguish from UC symptoms, making it difficult to assess whether the treatment is helping or hurting.

Opportunistic infections. Many people with UC are already on immunosuppressants that raise infection risk. Adding antibiotics shifts that risk profile further.

What This Means for Patients

The Cochrane reviewers called for larger, better-standardised clinical trials before antibiotics can be routinely recommended for UC. They emphasised that any use should weigh the potential benefit against the risk of resistance and side-effects on a case-by-case basis.

Right now, antibiotics are not a standard first-line or maintenance therapy for UC. But the research is active, and specific situations, such as a concurrent gut infection or certain refractory cases, may warrant speaking with your specialist or care team about whether antibiotics have a role.

This is not a treatment decision to make independently. Antibiotic regimens for UC should only be used under specialist guidance.

If you have ulcerative colitis and are considering antibiotic treatment, consult your doctor or specialist before making any changes to your care plan.